{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:15:07Z","timestamp":1773458107155,"version":"3.50.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T00:00:00Z","timestamp":1403481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0100478","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T20:27:53Z","timestamp":1403555273000},"page":"e100478","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":26,"title":["Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons"],"prefix":"10.1371","volume":"9","author":[{"given":"Paolo","family":"Verdecchia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"Reboldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,6,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-147-8-200710160-00018","article-title":"Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation","volume":"147","author":"RG Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH14-03-0228","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel","volume":"111","author":"S Husted","year":"2014","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options\u2014why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"BN Beasley","year":"2011","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"AJ Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"JJ You","year":"2012","journal-title":"Chest"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"GY Lip","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"LH Rasmussen","year":"2012","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCOUTCOMES.112.966572","article-title":"Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation","volume":"5","author":"WL Baker","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","article-title":"An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation","volume":"108","author":"S Mantha","year":"2012","journal-title":"Thromb Haemost"},{"key":"ref14","first-page":"330","article-title":"Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis","volume":"31","author":"J Harenberg","year":"2012","journal-title":"Int Angiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e77694","DOI":"10.1371\/journal.pone.0077694","article-title":"New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons","volume":"8","author":"P Sardar","year":"2013","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews","volume":"338","author":"F Song","year":"2009","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jacc.2012.05.012","article-title":"Danger ahead: watch out for indirect comparisons!","volume":"60","author":"CP Cannon","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1160\/TH12-07-0463","article-title":"Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what&apos;s next","volume":"108","author":"J Harenberg","year":"2012","journal-title":"Thromb Haemost"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1160\/TH12-06-0438","article-title":"Indirect comparison studies\u2014are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation","volume":"108","author":"F Skjoth","year":"2012","journal-title":"Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"SJ Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","article-title":"Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics","volume":"22","author":"RB D\u2032Agostino Sr","year":"2003","journal-title":"Stat Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/sim.1454","article-title":"The use of putative placebo in active control trials: two applications in a regulatory setting","volume":"22","author":"S Durrleman","year":"2003","journal-title":"Stat Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/009286150103500212","article-title":"Statistical methods for comparison to placebo in active-control trials","volume":"35","author":"V Hasselblad","year":"2001","journal-title":"Drug Info J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.jacc.2005.07.062","article-title":"Trials and tribulations of non-inferiority: the ximelagatran experience","volume":"46","author":"S Kaul","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.1315","article-title":"Some fundamental issues with non-inferiority testing in active controlled trials","volume":"22","author":"HM James Hung","year":"2003","journal-title":"Stat Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1081\/BIP-120037178","article-title":"Alternatives for discounting in the analysis of noninferiority trials","volume":"14","author":"SM Snapinn","year":"2004","journal-title":"J Biopharm Stat"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e000269","DOI":"10.1136\/bmjopen-2011-000269","article-title":"UK stroke incidence, mortality and cardiovascular risk management 1999\u20132008: time-trend analysis from the General Practice Research Database","volume":"1","author":"S Lee","year":"2011","journal-title":"BMJ Open"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/CIRCULATIONAHA.107.695163","article-title":"Challenges of establishing new antithrombotic therapies in atrial fibrillation","volume":"116","author":"SJ Connolly","year":"2007","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/pst.509","article-title":"Indirect comparisons in the comparative efficacy and non-inferiority settings","volume":"10","author":"S Snapinn","year":"2011","journal-title":"Pharm Stat"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/sim.3073","article-title":"Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials","volume":"27","author":"S Snapinn","year":"2008","journal-title":"Stat Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.thromres.2005.08.007","article-title":"Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis","volume":"118","author":"GY Lip","year":"2006","journal-title":"Thromb Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","volume":"323","author":"JP Kistler","year":"1990","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group","volume":"342","author":"PJ Koudstaal","year":"1993","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian Atrial Fibrillation Anticoagulation (CAFA) Study","volume":"18","author":"SJ Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation Study. Final results","volume":"84","author":"R McBride","year":"1991","journal-title":"Circulation"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study","volume":"1","author":"P Petersen","year":"1989","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"MD Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"HC Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1742-1241.2009.02072.x","article-title":"Indirect comparisons of treatments based on systematic reviews of randomised controlled trials","volume":"63","author":"SJ Edwards","year":"2009","journal-title":"Int J Clin Pract"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"DC Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"JP Jansen","year":"2011","journal-title":"Value Health"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"BF Gage","year":"2001","journal-title":"JAMA"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","volume":"276","author":"A Oler","year":"1996","journal-title":"JAMA"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"EM Antman","year":"1999","journal-title":"Circulation"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"CT Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Skjoth F, Larsen TB, Rasmussen LH, Lip GY (2014) Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 111. Epub ahead of print.","DOI":"10.1160\/TH14-02-0118"},{"key":"ref48","unstructured":"Food and Drug Administration (2010) Guidance for Industry: Non-Inferiority Clinical Trials. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM202140.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM202140.pdf<\/ext-link>. Accessed 2 January 2014."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0100478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T23:35:30Z","timestamp":1716852930000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0100478"}},"subtitle":[],"editor":[{"given":"Adrian V.","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,23]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0100478","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,23]]}}}